홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
TCRX
#3152
TScan Therapeutics, Inc. Common Stock
1.0
6
-3.64%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-3.64%
월간 변동
-4.50%
6달 변화
-43.32%
년간 변동율
-48.29%
이전 종가
1.1
0
Open
1.0
6
Bid
Ask
Low
1.0
6
High
1.0
6
양
6
마켓
주식
헬스케어
TCRX
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2021
2022
2023
2024
TTM
Cash from operating activities
48.68 M
66.5 M
61.36 M
110.82 M
130.73 M
Cash from investing activities
9.94 M
4.22 M
60.76 M
52.61 M
67.25 M
Cash from financing activities
189.67 M
29.36 M
135.44 M
208.76 M
46.1 M
Free cash flow
38.74 M
62.28 M
58.21 M
107 M
125.61 M
뉴스
TScan completes enrollment in trial cohort, receives FDA clearance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Tscan 테라퓨틱스, ASH 행사 후 BTIG ’중립’ 등급 유지
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event
TScan to host KOL event discussing updated ALLOHA trial data
모건 스탠리, Tscan Therapeutics 주식 투자의견 강등
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials
Tscan Therapeutics Q3 실적, 수익 예상치를 넘어